文献速递儿童血液肿瘤与免疫

CCLG-ALL 2008方案治疗儿童T细胞急性淋巴细胞白血病疗效分析

[Outcome of children with T cell acute lymphoblastic leukemia treated with Chinese Children Leukemia Group acute lymphoblastic leukemia (CCLG-ALL) 2008 protocol].
PubMed 文献 · Zhonghua Er Ke Za Zhi · 2019-01-01

该回顾性研究分析了84例初诊T-ALL患儿采用CCLG-ALL 2008方案治疗的临床特征与结局,中危组40%、高危组60%,5年OS和EFS分别为(63±6)%和(60±6)%。中危组长期生存显著优于高危组,危险度分组是预后重要影响因素。

要点

  • 84例T-ALL患儿中危组40%、高危组60%,5年OS(63±6)%、EFS(60±6)%。
  • 中危组5年OS(77±7)%、EFS(75±8)%均显著优于高危组(53±8)%、(49±8)%。
  • CCLG-ALL 2008危险度分组是T-ALL患儿预后的重要影响因素(OR=3.313,95%CI 1.165~9.422,P=0.025)。

核心结论

  • 按照CCLG-ALL 2008方案进行危险度分组治疗,中危组T-ALL患儿的长期生存明显优于高危组。

研究设计与样本

  • 回顾性分析中国医学科学院血液病医院2008年4月至2015年4月采用CCLG-ALL 2008方案治疗的初诊T-ALL患儿84例(男63例、女21例)。
  • 采用Kaplan-Meier分析评估总生存率(OS)和无事件生存率(EFS),采用COX回归模型评估OS、EFS的影响因素。

主要发现

  • 84例患儿中发病时年龄<10岁者56例(67%),初诊时外周血白细胞计数≥50×10(9)/L者70%(59/84)。
  • 泼尼松治疗敏感率56%(47/84),VDLD诱导第33天完全缓解(CR)率88%(74/84),VDLD联合CAM第80天总CR率94%(79/84)。
  • 复发率24%(20/84),20例复发患儿中超早期复发13例(65%)、早期复发6例(30%)、晚期复发1例(5%)。
  • 随访期间死亡28例,总病死率33%,其中因本病复发或未缓解死亡22例,化疗后并发严重感染死亡2例。
  • 84例患儿5年OS、EFS分别为(63±6)%和(60±6)%。

关键数值与推荐

  • 中危组与高危组泼尼松敏感率分别为100%(34/34)和26%(13/50)(χ(2)=3.237,P<0.05)。
  • 中危组与高危组VDLD诱导第33天CR率分别为100%(34/34)和80%(40/50)(χ(2)=2.767,P<0.05)。
  • 中危组与高危组复发率分别为12%(4/34)和32%(16/50)(χ(2)=4.245,P<0.05),病死率分别为21%(7/34)和42%(21/50)(χ(2)=3.198,P<0.05)。
  • 中危组与高危组5年OS分别为(77±7)%和(53±8)%,5年EFS分别为(75±8)%和(49±8)%(χ(2)=4.235、3.875,P均<0.05)。
  • COX多因素回归显示危险度分组是T-ALL患儿预后的重要影响因素(OR=3.313,95%CI 1.165~9.422,P=0.025)。

临床怎么用

  • 采用CCLG-ALL 2008方案对儿童T-ALL进行危险度分组治疗时,中危组长期生存优于高危组。
  • 高危组复发率和病死率较高,需关注其预后并加强相应管理。

局限性

  • 本研究为单中心回顾性分析,样本量84例。
  • 随访时间42.0(0.3~120.0)个月,部分患儿随访时间较短。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To evaluate the efficacy of the Chinese Children's Leukemia Group (CCLG) acute lymphoblastic leukemia (ALL) 2008 protocol (CCLG-ALL 2008) in the treatment of children's T-cell acute lymphoblastic leukemia (T-ALL). Methods: Clinical characteristics and outcomes of 84 newly diagnosed T-ALL children (63 males and 21 females) treated with CCLG-ALL 2008 protocol from April 2008 to April 2015 in the Department of Pediatric Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences were analyzed retrospectively. Kaplan-Meier analysis was used to evaluate the overall survival (OS) and event free survival (EFS), and COX regression was used to evaluate the influencing factors of OS and EFS. Results: (1) Baseline data: 84 children were included, 56 cases (67%) of children were younger than 10 years old. Patients whose white blood cell count≥50×10(9)/L ranked 70% (59/84). Karyotype: 58% (49/84) with normal karyotype, 10% (8/84) with abnormality of chromosome 11, 8%(7/84) with abnormality of chromosome 9, 2%(2/84) with abnormality in both chromosome 11 and chromosome 9, 8% (7/84) with other complex karyotypes. Fusion gene: 33%(28/84) were SIL-TAL1 positive. The patients were grouped by CCLG-ALL 2008 risk score, 40% (34/84) were in the intermediate risk group and 60% (50/84) in the high risk group. (2) Treatment efficacy: 84 cases were followed up until May 30, 2018. The follow-up time was 42.0 (0.3-120.0) months. The sensitivity rate of prednisone treatment was 56% (47/84); the complete response (CR) rate after the induction therapy of vincristine+daunoblastina+L-asparaginase+dexamethasone (VDLD)(d 33) was 88% (74/84); the total CR rate after VDLD induction combined with cyclophosphamide+cytarabine+6-mercaptopurine (CAM) treatment (d80) was 94% (79/84); the recurrence rate was 24% (20/84). Among the 20 recurrent cases, there were 13 cases (65%) with ultra-early recurrence (within 18 months after diagnosis), 6 cases (30%) with early recurrence (18 to 36 months after diagnosis); 1 patient (5%) with late recurrence (over 36 months after diagnosis). During the follow-up period, twenty-eight children (33%) died (22 cases with recurrence or suspending treatment without remission, 2 cases with infection, 1 case of sudden death in chemotherapy, 1 patient failed in transplantation, 1 patient with severe cirrhosis, and 1 patient with unknown cause). (3) Kaplan-Meier analysis: the 5-year OS and EFS of the 84 children were (63±6)% and (60±6)% respectively. (4) Efficacy in different risk groups: prednisone sensitivity rates in the two different risk groups were 100% (34/34) and 26% (13/50), respectively (χ(2)=3.237, P<0.05). The CR rates at the end of VDLD induction therapy (d 33) were 100% (34/34) and 80% (40/50), respectively (χ(2)=2.767, P<0.05). The recurrence rate of children in the two groups was 12% (4/34) and 32% (16/50), respectively (χ(2)=4.245, P<0.05).The mortality rates of the two groups were 21% (7/34) and 42% (21/50), respectively (χ(2)=3.198, P<0.05). Kaplan-Meier analysis showed that the 5-year OS of the two groups were (77±7)% and (53±8)%; and the 5-year EFS of the two groups were (75±8)% and (49±8)% (χ(2)=4.235, 3.875, both P<0.05) . (5) COX multivariate regression analysis showed that the classification of risk according to CCLG-ALL 2008 was an important factor influencing the prognosis of children with T-ALL (OR=3.313, 95% CI 1.165-9.422, P=0.025). Conclusions: The results of the risk group treatment according to the CCLG-ALL 2008 protocol showed that the long-term survival of children with middle risk was significantly better than that of children at high risk. 目的: 评价中国儿童白血病组织(CCLG)急性淋巴细胞白血病(ALL)2008方案(CCLG-ALL 2008)对儿童急性T淋巴细胞白血病(T-ALL)的临床疗效。 方法: 回顾性分析中国医学科学院血液病医院(血液学研究所)儿童血液病诊疗中心2008年4月至2015年4月采用CCLG-ALL 2008方案治疗的初诊T-ALL患儿84例(男63例、女21例)的临床特点、疗效,采用Kaplan-Meier分析评估患儿总生存率(OS)和无事件生存率(EFS),采用COX回归模型评估OS、EFS的影响因素。 结果: (1)一般特征:84例患儿中发病时年龄<10岁者56例(67%);初诊时外周血白细胞计数(WBC)≥50×10(9)/L者70%(59/84);正常核型58%(49/84),含有11号染色体异常10%(8/84),含有9号染色体异常8%(7/84),既含有11号染色体异常又含有9号染色体异常2%(2/84),其他复杂核型8%(7/84);SIL-TAL1阳性者33%(28/84);CCLG-ALL 2008危险度分组,中危组40%(34/84),高危组60%(50/84)。(2)疗效反应:截至2018年5月30日,随访时间42.0(0.3~120.0)个月。泼尼松治疗敏感率56%(47/84);长春新碱+柔红霉素+门冬酰胺酶+地塞米松(VDLD)诱导治疗结束(第33天)完全缓解(CR)率88%(74/84);VDLD诱导治疗及环磷酰胺+阿糖胞苷+6-巯基嘌呤(CAM)治疗结束后(第80天)总CR率94%(79/84);复发率24%(20/84),20例复发患儿中超早期复发13例(65%)、早期复发6例(30%)、晚期复发1例(5%)。随访期间死亡28例,总病死率33%,其中因本病复发或未缓解导致死亡22例,因化疗后并发严重感染导致死亡2例,化疗中猝死1例,移植失败导致死亡1例,化疗后重度肝硬化导致死亡1例,死因不详1例。(3)Kaplan-Meier分析84例患儿5年OS、EFS分别为(63±6)%和(60±6)%。(4)不同危险组疗效:中、高危两组患儿泼尼松敏感率分别为100%(34/34)和26%(13/50)(χ(2)=3.237,P<0.05);VDLD诱导治疗结束(第33天)CR率分别为100%(34/34)和80%(40/50)(χ(2)=2.767,P<0.05);两组患儿复发率分别为12%(4/34)和32%(16/50)(χ(2)=4.245,P<0.05);两组患儿病死率分别为21%(7/34)和42%(21/50)(χ(2)=3.198,P<0.05)。Kaplan-Meier分析中危和高危两组患儿5年OS分别为(77±7)%和(53±8)%,5年EFS分别为(75±8)%和(49±8)%(χ(2)=4.235、3.875,P均<0.05)。(5)COX多因素回归分析显示,危险度分组的划分是T-ALL患儿预后的重要影响因素(OR=3.313,95%CI:1.165~9.422,P=0.025)。 结论: 按照CCLG-ALL 2008方案进行危险度分组治疗,中危组T-ALL患儿的长期生存明显优于高危组。.

来源:Zhonghua Er Ke Za Zhi,查看原文。版权归原作者所有。

引用

  1. Liu XM, Chen XJ, Zou Y, et al. [Outcome of children with T cell acute lymphoblastic leukemia treated with Chinese Children Leukemia Group acute lymphoblastic leukemia (CCLG-ALL) 2008 protocol]. Zhonghua Er Ke Za Zhi. 2019. PMID: 31594062. doi:10.3760/cma.j.issn.0578-1310.2019.10.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。